US POLIMEX , INC. – Trademark Portfolio

Entity Type: 03

US POLIMEX , INC. holds 2 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 35 (Advertising & Business) — 1 filings in this category. The portfolio also extends into Class 5 (Pharmaceuticals) across 2 Nice Classification classes. Currently, 2 trademarks are registered. Notable registered marks include VITAMY NUTRITION and USP US POLIMEX A GLOBAL SYNERGY. The owner is based in Garden Grove, CA.

12651 Trask Ave

Garden Grove, CA 92843

2 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Trademark Classifications

US POLIMEX , INC.'s trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

35
Advertising & Business (1 filing)

Advertising; business management; business administration; office functions

5
Pharmaceuticals (1 filing)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

Frequently Asked Questions

How many trademarks does US POLIMEX , INC. have?

US POLIMEX , INC. has 2 U.S. trademarks filed with the USPTO. Of these, 2 registered.

What trademark classes does US POLIMEX , INC. file in?

US POLIMEX , INC. files trademarks across 2 Nice Classification classes. The most active classes are Class 35 (Advertising & Business), Class 5 (Pharmaceuticals). Class 35 covers advertising; business management; business administration; office functions.

What are US POLIMEX , INC.'s most well-known trademarks?

US POLIMEX , INC.'s registered trademark portfolio includes well-known marks such as VITAMY NUTRITION and USP US POLIMEX A GLOBAL SYNERGY. These are among 2 currently registered trademarks in the portfolio.

What is US POLIMEX , INC.'s trademark registration success rate?

US POLIMEX , INC. has a 100% trademark registration rate, with 2 out of 2 resolved applications resulting in successful registration. Currently, 0 applications are pending review.